View profile

FarmaKology-Popular nausea medications linked to increased stroke risk

Revue
 
 

FarmaKology

March 24 · Issue #101 · View online

FarmaKology is a newsletter that brings you the latest news, research, job opportunities in the Pharma world, and much more! If you would like to be featured in the newsletter, sponsor an issue, or need anything, please feel free to get in touch with me at "abdul@farmakology.com".


Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to abdul@farmakology.com, and happy to have you featured on our newsletter (+15K Subscribers )!

FarmaKology-Popular nausea medications linked to increased stroke risk
FarmaKology-Popular nausea medications linked to increased stroke risk
Novo Banking
Novo Banking
Today's Company
Anavo Therapeutics
Anavo Therapeutics
Anavo Therapeutics
Anavo Therapeutics is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades. We have attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators. In oncology, Anavo is developing multiple first-in-class therapeutic programs and will build on partnerships around its platform to establish a rich pipeline across several indications.Anavo is backed by blue-chip investors M Ventures, INKEF Capital, Taiho Ventures, and Bioqube Ventures.
News
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration (FDA) approved a label update for Cabenuva (cabotegravir, rilpivirine) making the oral lead-in with cabotegravir and rilpivirine tablets optional. Oral cabotegravir and rilpivirine can be taken for a month to assess tolerability to the medicines prior to initiating cabotegravir and rilpivirine injections, a regimen co-developed as part of a collaboration with the Janssen Pharmaceutical Companies of Johnson & Johnson, but this oral lead-in is now optional after clinical trial data demonstrated similar safety and efficacy profiles for both initiation methods (with or without the oral lead-in).
Cefiderocol has completed three global trials (a Phase 2 trial [APEKS-cUTI] in patients with complicated urinary tract infections, a Phase 3 trial in patients with carbapenem-resistant gram-negative bacterial infections [CREDIBLE-CR], and a Phase 3 trial in patients with nosocomial pneumonia [APEKS-NP]) and has been approved by the U.S. Food and Drug Administration (FDA) and the European Commission (EC). Based on the results of these clinical trials, Shionogi has filed for approval to manufacture and sell cefiderocol in Japan.
Moderna, Inc. , a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced the finalization of a strategic partnership with the Australian Federal Government to establish a state-of-the-art, domestic mRNA vaccine manufacturing facility in Australia. This finalizes the agreement in principle with the Australian Federal Government announced  in December 2021.
Pfizer Inc. today announced that its respiratory syncytial virus vaccine candidate, PF-06928316 or RSVpreF, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age or older.
Research & Study
Podcast
Stream episode Pharma markets their drugs to young adults — so why don't they include them in clinical trials? by First Opinion Podcast podcast | Listen online for free on SoundCloud
Job Opportunities
Upcoming Webinar & Event
Video
Vaccine Efficacy Numbers, Explained | WSJ
FarmaKology
FarmaKology
Did you enjoy this issue?
In order to unsubscribe, click here.
If you were forwarded this newsletter and you like it, you can subscribe here.
Powered by Revue